Subscribe To

Price Alert Latest News Economic Calendar News

AVIR / Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - CEO and Founder John Vavricka - CCO Janet Hammond - CDO Andrea Corcoran - CFO and Executive President, Legal Conference Call Participants Hannah Adeoye - JPMorgan Matthew Harrison - Morgan Stanley Umer Raffat - Evercore Tim Lugo - William Blair Nik Gasic - SVB Securities Operator Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Conference Call. Read More

Demo Live Account See Partner Details

Content Topics

Atea

Pharmaceuticals

Inc

AVIR

Jean

Pierre

Sommadossi

Pharmaceuticals

avir

Jean pierre

results

Earnings

Transcript

Stock

Posted: Nov 7 2022, 22:29

Author Name: Seeking Alpha

AVIR News

By GlobeNewsWire
November 1, 2023

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged i

By GlobeNewsWire
June 5, 2023

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged i

By Seeking Alpha
May 8, 2023

Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2023 Results Conference Call May 8, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior Vice Presi

By GlobeNewsWire
May 1, 2023

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in

By Seeking Alpha
February 28, 2023

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Jonae Barnes - Senior VP,

By GlobeNewsWire
February 7, 2023

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today an

By Seeking Alpha
November 7, 2022

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & C

By Seeking Alpha
August 8, 2022

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2022 Results - Earnings Call Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jonae Barnes - Senior Vice P

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

AVIR / Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call Transcript

Atea

Pharmaceuticals

Inc

AVIR

Jean

Pierre

Sommadossi

Pharmaceuticals

avir

Jean pierre

results

Earnings

Transcript

Stock

AVIR News

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

Atea Pharmaceuticals, Inc. (AVIR) Q1 2023 Earnings Call Transcript

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

Atea Pharmaceuticals, Inc. (AVIR) Q4 2022 Earnings Call Transcript

Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call Transcript

Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2022 Results - Earnings Call Transcript